智通财经网·2025-08-05 08:58Core Viewpoint - Xinhua Pharmaceutical (000756.SZ) has received approval from the National Medical Products Administration for the registration of Finasteride tablets, which are indicated for the treatment and management of benign prostatic hyperplasia (BPH) [1] Company Summary - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., is responsible for the newly approved Finasteride tablets [1] - Finasteride tablets are designed to reduce the risk of acute urinary retention and the need for surgical procedures such as transurethral resection of the prostate (TURP) and prostatectomy [1] Industry Summary - Finasteride tablets can help shrink enlarged prostates, improve urinary flow, and alleviate symptoms associated with benign prostatic hyperplasia [1]